Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.45B P/E 15.65 EPS this Y -43.40% Ern Qtrly Grth -10.20%
Income 115.91M Forward P/E 15.47 EPS next Y 6.20% 50D Avg Chg 7.00%
Sales 1.53B PEG -0.66 EPS past 5Y 9.86% 200D Avg Chg -10.00%
Dividend N/A Price/Book 1.23 EPS next 5Y -18.32% 52W High Chg -33.00%
Recommedations 2.60 Quick Ratio 2.87 Shares Outstanding 107.64M 52W Low Chg 18.00%
Insider Own 1.14% ROA 2.16% Shares Float 108.01M Beta 0.60
Inst Own 17.21% ROE 8.93% Shares Shorted/Prior 8.13M/9.43M Price 13.30
Gross Margin 50.64% Profit Margin 3.97% Avg. Volume 956,414 Target Price 11.40
Oper. Margin 16.59% Earnings Date - Volume 634,963 Change -0.60%
About Veradigm Inc.

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Veradigm Inc. News
08/29/24 Veradigm Named as the Top Vendor for End-to-End Revenue Cycle Management Solutions
08/06/24 Positive Impact Observed at Many Orthopedic Practices Utilizing Veradigm Coding Services
06/12/24 Black Book ranks Veradigm Payer Analytics the #1 Overall Payer Analytics Solutions Vendor in 2024
05/30/24 Veradigm Payerpath Rated Highest in Client Satisfaction
05/28/24 Veradigm Announces Leadership Updates
05/28/24 Veradigm to Explore Strategic Alternatives and Reaffirms 2024 Guidance
04/09/24 Veradigm Network Solution Practice Fusion EHR Receives Top Ambulatory Rankings
03/14/24 Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
03/13/24 Veradigm Announces Initial Financial Guidance for Fiscal 2024
03/04/24 Veradigm Completes Acquisition of ScienceIO
03/04/24 Veradigm to Participate in Barclays 26th Annual Global Healthcare Conference
02/28/24 Sprinklr Set to Join S&P SmallCap 600
02/28/24 Veradigm to Participate in TD Cowen Annual Health Care Conference
02/28/24 Veradigm Receives Expected Delisting Notice from Nasdaq
02/27/24 Veradigm Inc (MDRX) Announces Strategic Acquisition of ScienceIO to Enhance AI Capabilities
02/27/24 Veradigm to Acquire ScienceIO
02/27/24 Veradigm Provides Update on its Financial Restatement Process
02/22/24 Veradigm to Highlight New EHR-Integrated Care Gap Alert Solution at ViVE 2024 Conference
02/20/24 Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.
02/13/24 Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health
MDRX Chatroom

User Image TheYoungerPliny Posted - 1 day ago

Is it not about time for Veradigm $MDRX management to start apologizing to its shareholders about the ridiculous delays in filing the (get this) 2022, 2023 and H1 2024 financial results? The ‘strategic’ smokescreen (buyout or merger plans) is becoming less interesting with every month that passes. Come on @TomLangan speak out!

User Image TheYoungerPliny Posted - 6 days ago

@IOMASS what does a high volume, positive price/volume like this usually signify? $MDRX

User Image IOMASS Posted - 6 days ago

$MDRX Another elevated volume day - this situation is so goofy maybe we'll have a Merger Monday event.

User Image TheYoungerPliny Posted - 1 week ago

The view of Gemini on the Veradigm $MDRX buyout candidates. Let’s see. https://gemini.google.com/app/4938517b1fec0f75

User Image trufflehog Posted - 1 week ago

$MDRX who the hell let 1.24 million shares go below 10....for the love of God raise the ask!

User Image IOMASS Posted - 1 week ago

$MDRX nice volume today - buy side bias with $9.86+ VWAP - cmon update…

User Image IOMASS Posted - 1 week ago

$MDRX FWIW TD Cowen reiterated $15 PT Buy

User Image TheYoungerPliny Posted - 2 weeks ago

$MDRX Veradigm doesn’t need the revolver https://investor.veradigm.com/static-files/32b8707d-691e-4117-8d86-6bfdfb50f100

User Image TheYoungerPliny Posted - 08/29/24

$MDRX

User Image IOMASS Posted - 08/27/24

$MDRX Patience is certainly a virtue @ MDRX - given the share redistribution post the delisting and the interim status of management, I’ve gotta believe a sale transaction @ a reasonable valuation is the overwhelming likely outcome of strategic review - valuations are not great right now for healthcare data/analytics but current MDRX valuation is low and a sale needs to happen IMO…

User Image trufflehog Posted - 08/27/24

$MDRX break 10!

User Image 6RickyBobby9 Posted - 08/21/24

$MDRX Given these poor valuations, why won’t they just re-enlist?

User Image TheYoungerPliny Posted - 1 month ago

Roche $ROG.SW owns #Flatiron Health and Stephanie Reisinger, ex #Veradigm is its Senior VP and General Manager, Real-World Evidence (RWE). A dealmaker’s dream? $MDRX https://search.app/?link=https%3A%2F%2Fresources%2Eflatiron%2Ecom%2Fpress%2Fpress%2Drelease%2Fstephanie%2Dreisinger%2Dto%2Dlead%2Dflatiron%2Dhealths%2Dreal%2Dworld%2Devidence%2Dbusiness&utm_source=igadl%2Cigatpdl%2Csh%2Fx%2Fgs%2Fm2%2F5

User Image TheYoungerPliny Posted - 1 month ago

Veradigm, a Chicago-based provider of healthcare data and technology solutions, collected initial bids recently for a potential sale, three sources familiar wit… $MDRX $SPY https://search.app/1Sn1p9UXYxg7KD9o9

User Image TheYoungerPliny Posted - 1 month ago

$MDRX In yesterday’s SEC filing Veradigm $MDRX is reporting quite a serious (12 mln) cash drain. Can anyone pinpoint a reason?

User Image NewsAndFilings Posted - 1 month ago

Yesterday's Recap: $BMXC Letter of Intent to Acquire Kona Gold, LLC $RMSL Shareholder Letter $AAWH Expands Non-Medical Cannabis Access in Ohio $MDRX Positive Impact using Veradigm Coding Services

User Image IOMASS Posted - 1 month ago

$MDRX Serious and pathetic question : can MDRX go through strategic review without ever releasing restated financials? You’d think public financials are necessary to evaluate any transaction…

User Image Windee Posted - 1 month ago

$MCK All the way! Nice vertical intergration $ORLY $HSIC $MDRX

User Image IOMASS Posted - 07/31/24

$MDRX The unofficial $10 lid has now been in place since the end of May - a $7.50 lid was in place previous 3 months - talk about controlled trading!

User Image TheYoungerPliny Posted - 07/29/24

Almost every day the $MDRX marketmaker opens the dance with this quote at around 2.600 shares. After which the price will fall back to around 9.70 Balancing the books? $SPY

User Image IOMASS Posted - 07/29/24

$MDRX At last count, top holders control almost 50% of Company - they have the keys...

User Image IOMASS Posted - 07/29/24

$MDRX Maybe we’re in luck with Chuck.

User Image TheYoungerPliny Posted - 2 months ago

Some healthcare technology companies deliver clinical data for biopharma and health plans. Some turn that data into insights. Others serve providers directly though point-of-care clinical software or outreach platforms. Only Veradigm does it all. #Veradigm #TransformingHealth $SPY $MDRX

User Image trufflehog Posted - 2 months ago

$MDRX lots of volume today. Maybe we're lose to a takeout bid? Can we get this over 10 sustainably, maybe?

User Image TheYoungerPliny Posted - 2 months ago

$MDRX It’s only a matter of time. Big pharma is on the move.

User Image TheYoungerPliny Posted - 2 months ago

$MDRX In a way I can understand why everything is taking so long at #Veradigm. While the accounting team is working “diligently” on the 2022-23 and Q1 and Q2 2024 numbers, a due diligence team from $ICLR $LLY or $NVS is driving them nuts with questions. Patience, grasshopper…

User Image IOMASS Posted - 2 months ago

$MDRX Finally breached $10 on open - I guess nice to see but just waiting on news...

User Image TheYoungerPliny Posted - 2 months ago

$MDRX

User Image TheYoungerPliny Posted - 06/29/24

Interesting background read on why the eventual valuation of Veradigm $MDRX could be a multiple of the current depressed $9,50 $SPY Explore the transformative power of Real-World Data (RWD) and Real-World Evidence (RWE) in contemporary clinical trials. https://www.octalsoft.com/unlocking-the-value-of-rwdreal-world-data-and-rwereal-world-evidence-in-modern-clinical-trials/

User Image TheYoungerPliny Posted - 06/21/24

Veradigm $MDRX has today awarded its Board and mgmt substantial stock packages vesting in 3 annual steps. Effectively locking up commitment in the runup to an acquisition. The plot thickens…

Analyst Ratings
TD Cowen Buy May 28, 24
Deutsche Bank Hold Mar 19, 24
RBC Capital Outperform Jan 19, 24
Barclays Equal-Weight Jan 3, 24
Stephens & Co. Equal-Weight Nov 14, 23
Stephens & Co. Equal-Weight Oct 10, 23
Argus Research Hold Jul 6, 23
Stephens & Co. Equal-Weight Apr 12, 23
Piper Sandler Neutral Feb 1, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Jones Leah Chief Financial Offi.. Chief Financial Officer Aug 15 Sell 17.65 3,945 69,629 109,055 08/18/22
Poulton Richard J. CEO CEO Aug 15 Sell 17.45 20,000 349,000 732,517 08/16/22
Black Paul Director Director Jun 10 Sell 16.5816 60,000 994,896 1,254,631 06/13/22
Black Paul Director Director Jun 06 Sell 17.33 140,450 2,433,998 1,314,631 06/07/22
Black Paul Director Director May 17 Sell 18.1792 50,000 908,960 1,529,649 05/19/22
Black Paul Director Director May 13 Sell 18.0138 50,000 900,690 1,579,649 05/16/22
Black Paul CEO CEO Mar 10 Sell 21.8676 60,000 1,312,056 1,389,199 03/10/22
Poulton Richard J. President & CFO President & CFO Feb 15 Sell 20.78 20,000 415,600 521,593 02/16/22